A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies

"TAK-441 will be administered as an oral tablet as follows:~Patients enrolled in the dose escalation cohorts will receive:~* A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed~* Continuous daily dosing on Days 8 through 28 in Cycle 1~* In subsequent cycles, continuous daily dosing over 21 days, repeated continuously~Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle"